MICROVASCULAR THERAPEUTICS Inc

Microvascular Therapeutics is a clinical stage biopharma company pioneering in theranostics and ultrasound contrast agents.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Tucson, AZ, USA
  • Currency USD
  • Founded November 2009
  • Employees 7
  • Incorporation Type C-corp
  • Website mvtpharma.com

Company Summary

Microvascular Therapeutics is a clinical-stage biotech company developing cutting-edge micro and nanobubble technology that will unlock the potential of ultrasound in diagnosis and therapy. Our microbubble, CardiSon, is in Phase IIb of clinical trials and serves as a platform for nanobubbles. The nanobubbles oscillate when they enter the acoustic field and can be used for non-thermal focused ultrasound surgery, blood clot disruption, and more.

Team

  • Emmanuelle Meuillet
    Chief Operating and Scientific Officer

    >25 year experience in R&D, acquiring and managing >$15M non-diluting funds

  • Evan C Unger
    Chairman of the Board

    Serial Entrepreneur, Successful exit (>20X ROI), Inventor (>120 US Issued patents, Develop the world #1 best-selling ultrasound contrast agent (Sold as Definity and commercialized by Lantheus, a $5B market cap company)

  • Marty Rosenberg
    Chief Medical Officer

    > 30years of expertise in contrast agents. He joined Squibb Diagnostics in 1990 and worked on the clinical development and approval of two novel oral contrast agents from ImarX pharmaceuticals: SonoRx and LumenHance. In 1996, he was hired by Bristol-Myers Squibb Medical Imaging, formerly DuPont Pharma, to develop the ultrasound contrast agent Definity (DMP-115), also invented by Imarx pharmaceuticals. He retired from Bayer after 16 years

  • David Lim
    Director of Finance

    David has extensive experience in financial markets both public and private, and asset management industry. He Co-Founded Washington Square Capital, which focuses on making acquisitions of privately held businesses. Previously, he worked as a trader for a subsidiary of Royal Bank of Canada, with $40B in asset

Previous Investors

  • Evan Unger
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free